According to reports from the Zhichong Finance app, Radionetics Oncology recently announced a strategic partnership with Eli Lilly and Co to advance Radionetics' proprietary G protein-coupled receptor (GPCR) targeted small molecule radiopharmaceuticals. Radionetics Oncology is a biotechnology company dedicated to discovering and developing new GPCR-targeted radiopharmaceuticals for the treatment of various types of cancer, including breast cancer, lung cancer, and other diseases that have not been satisfactorily treated.

Under the terms of the agreement, Radionetics received a prepayment of $140 million. As part of the strategic arrangement, Eli Lilly and Co has the exclusive right to acquire Radionetics for $1 billion at the end of the exercise period. During the exercise period, Radionetics will continue to build its proprietary pipeline of therapeutic projects, including the development of GPCR-targeted small molecule radiopharmaceuticals using Radionetics' proprietary discovery platform.